share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14

HC Wainwright & Co.维持对加的夫肿瘤学的买入,将目标股价上调至14美元
Moomoo 24/7 ·  03/06 06:49

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $12 to $14.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱维持加的夫肿瘤学(纳斯达克股票代码:CRDF)的买入并将目标股价从12美元上调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发